Join
Live feed
·
PRReleasevia Quantisnow
Sensei Biotherapeutics Inc. logo

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

ByQuantisnow·Wall Street's wire, on your screen.
SNSE· Sensei Biotherapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SNSE (Sensei Biotherapeutics Inc.) and more on Quantisnow.